ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000

Heart Valve Diseases Clinical Trial

— Enable  

Official title:

ATS 3f Enable(tm) Aortic Bioprosthesis, Model 6000

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01116024
• Other study ID #: S2005 Rev. 17-MAY-2007
• Status: Completed
• Phase: N/A
• Start date: May 2006
• Est. completion date: August 2012

Study information

• Verified date: October 2017
• Source: Medtronic Cardiovascular
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, non-randomized, multi-center study designed to evaluate safety and effectiveness of the ATS 3f Enable Aortic Bioprosthesis in a patient population undergoing isolated aortic valve replacement with or without concomitant procedures. The Enable Aortic Valve is an equine pericardial stented bioprosthesis.

Description:

The ATS 3f Enable Aortic Bioprosthesis is intended for those patients whose prognosis without surgical replacement of the diseased natural valve is unacceptably poor in terms of survival and/or quality of life in the opinion of the attending physicians. For these patients, there are a number of widely accepted prosthetic heart valves in use.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 173
• Est. completion date: August 2012
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• The patient requires isolated aortic valve replacement with or without concomitant procedures such as coronary artery bypass or another valve repair. (The three remaining valves must be of native tissue).

• The patient is geographically stable and willing to return to the implant site for follow-up visits.

• The patient has been adequately informed of risks and requirements and consent to his/her participation in the clinical study.

• If this patient is female and of childbearing potential, patient has a negative pregnancy test within seven (7) days prior to the study procedure.

Exclusion Criteria:

• The patient requires replacement of two or more valves.

• The patient is < 20 years of age.

• The patient has a non-cardiac major or progressive disease, which in the Investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than 24 months.

• The patient is an intravenous drug and/or alcohol abuser.

• The patient presents with active endocarditis or other systemic infection.

• The patient has had previous valve replacement surgery, including previous implant and then explant of the ATS 3f Enable Aortic Bioprosthesis (Model 6000) or placement of a rigid annuloplasty ring in the mitral position.

• The patient is participating in concomitant research studies of investigational products.

• The patient presents with dilatation of the ascending aorta, Marfan Syndrome, Ehlers-Danlos syndrome, cystic medial degeneration, or other condition causing the ascending aorta to be irregular in geometry or physiology as seen via preoperative imaging.

• The patient has chronic renal failure.

Related Conditions & MeSH terms

• Heart Valve Diseases

Intervention

Device:
• ATS 3f Enable Aortic Bioprosthesis Model 6000
Replacement Aortic Heart Valve

Locations

Country	Name	City	State
Austria	Medical University of Vienna	Vienna
Germany	Johann Wolfgang Goethe University	Frankfurt
Germany	University Medical Center Freiburg	Freiburg
Germany	University Medical Center Kiel	Kiel
Germany	UKSH, Campus Lubeck	Lubeck
Poland	Medical University of Gdansk	Gdansk
Poland	Jagiellonian University	Krakow
Switzerland	Cardiac Surgery University Hospital Basel	Basel
Switzerland	Inselspital Bern	Bern
United Kingdom	John Radcliffe Hospital	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Cardiovascular

Countries where clinical trial is conducted

Austria,  Germany,  Poland,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Thromboembolism/Thrombosis	Valve related thromboembolism and valvular thrombosis.; Thrombosis was defined as any thrombus attached to or near the study valve that interfered with valve function in the absence of infection. The results are reported as linearized rate (percentage of participants per patient-year)	Five Years
Primary	Hemorrhage/Bleeding-Anticoagulant/Antiaggregant (All and Major)	Any episode of internal or external bleeding in subjects receiving anticoagulant and/or antiaggregant therapy.; Hemorrhage/Bleeding (No Anticoagulant/Antiaggregant): Any episode of internal or external bleeding in subjects not receiving anticoagulant and/or antiaggregant therapy.; The results are reported as linearized rate (percentage of participants per patient-year).	Five Years
Primary	Paravalvular Leaks (All and Major)	Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis (between the sewing ring and native annulus). Major Paravalvular leak was defined as any evidence of leakage of blood around the prosthesis, i.e. between the sewing ring and native annulus that requires surgical intervention.; The results are reported as linearized rate (percentage of participants per patient-year).	Five Years
Primary	Endocarditis	Endocarditis was defined in the protocol as any infection involving the study valve. Any structural/non-structural valvular dysfunction, thrombosis, or embolic event associated with study valve endocarditis was captured as endocarditis only.; The results are reported as linearized rate (percentage of participants per patient-year).	Five Years
Primary	Hemolysis	Blood data analysis was performed in order to identify whether particular complications and serious adverse events such as hemolysis occurred. Hemolysis in subjects with tissue valves - as evidenced by increased serum lactate dehydrogenase concentrations, decreased serum haptoglobin concentration, erythrocytopenia and reticulocytosis - is usually associated with paravalvular leakage or infection.	Five Years
Primary	Structural Valve Deterioration	Structural deterioration was defined as any change in the study valve function which resulted from an intrinsic abnormality that caused stenosis or regurgitation.; There were no cases of structural deterioration reported for the study.; The results are reported as linearized rate (percentage of participants per patient-year).	Five Years
Primary	Non-Structural Dysfunction	Any abnormality resulting in stenosis or regurgitation at the operated valve that is not intrinsic to the valve itself. Non-structural dysfunction refers to non-structural problems that result in dysfunction of an operated valve exclusive of thrombosis and infection diagnosed by reoperation, autopsy, or clinical investigation.; The results are reported as linearized rate (percentage of participants per patient-year).	Five Years
Primary	Re-operation, Explant, Repair	Reoperation was defined in the protocol as any operation to repair, alter, or replace the study valve. Included is reoperation for repair of paravalvular leak and explant.; The results are reported as linearized rate (percentage of participants per patient-year).	Five Years
Primary	Effectiveness Endpoint - NYHA Classification, Hemodynamic Performance	New York Heart Association (NYHA) classification to asses improvement of the cardiac status, Hemodynamic Performance analysis based on Doppler echocardiographic studies.; Class I: Patients with cardiac disease but without limitations of ordinary activity.; Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.; Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity results in fatigue, palpitations or anginal pain.; Class IV: Patients with cardiac disease resulting in inability to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency or anginal syndrome may be present even at rest. If any physical activity is undertaken discomfort is increased.	Five Years
Primary	Hemodynamic	Mean and peak pressure gradients from discharge through 5 years follow up. The gradient represents the difference in blood pressure across the valve.	Five Years
Primary	Hemodynamics - Effective Orifice Area	Effective orifice area (EOA) data.; The effective orifice area is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.	Five Years
Primary	Hemodynamics - Effective Orifice Area Index	The effective orifice area index is a measure of how much the heart valve prosthesis impedes blood flow through the aortic valve.	Five Years

External Links

•   Medtronic, Inc. Corporate Website